Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Inc (NYSE: TFX) is a global medical technology leader developing devices that enhance patient care across surgical, interventional, and critical care settings. This news hub provides investors and healthcare professionals with timely updates on TFX's clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative reporting on product innovations like the UroLift system, vascular access solutions, and anesthesia devices that demonstrate Teleflex's commitment to evidence-based medicine. Our curated news collection covers essential developments including quarterly earnings, FDA clearances, partnership announcements, and clinical trial outcomes.
Key updates focus on Teleflex's core therapeutic areas: minimally invasive surgical tools, critical care devices, and urology solutions. Stay informed about technologies improving procedural safety and healthcare economics through verified press releases and objective analysis.
Bookmark this page for consolidated access to Teleflex's latest progress in medical device innovation, financial performance data, and market expansion efforts. Regularly updated to serve as your primary resource for understanding TFX's role in advancing global medical standards.
Teleflex Incorporated (NYSE: TFX) has announced a worldwide recall of its Arrow-Trerotola™ Over-The-Wire PTD® Kit due to a defect where the inner lumen can detach from the device’s basket. This recall affects products manufactured between October 2019 and July 2021, classified as a Class I recall by the FDA. The company received seven complaints, with no reported long-term complications. Consumers are advised to discontinue use and return all affected products. The recall notice, including product codes and lot numbers, is available on their website.
Teleflex (NYSE: TFX) has been named the top large company in the MedReps.com Best Places to Work in Medical Sales 2022 survey. This marks the fifth consecutive year Teleflex has earned this honor. The survey, which included over 2,300 medical sales professionals, highlighted key factors such as pay, leadership, and culture as significant for employees when choosing an employer. Teleflex's leadership expressed pride in the award, emphasizing the company's commitment to innovation and employee engagement.
Teleflex Incorporated (NYSE: TFX) is participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 22 to December 2, 2021. A pre-recorded presentation will be available on their investor website at 10 AM ET on November 22. Additionally, 1x1 meetings are scheduled for December 2, which can be requested through Piper Sandler. Teleflex focuses on innovative medical technologies across various fields including vascular access and emergency medicine, aiming to enhance patient health and quality of life.
Teleflex has partnered with Explorer Surgical to enhance training for urologists using the UroLift® System. This collaboration introduces the Explorer Live digital platform, promoting remote learning and collaboration through an interactive digital playbook. Surgeons can access tailored surgical information, real-time education, and video capabilities during procedures. The UroLift System offers a minimally invasive solution for benign prostatic hyperplasia, improving patient outcomes and access to effective treatments.
Teleflex (NYSE: TFX) responded to the November 3, 2021, release of the CMS 2022 Medicare Physician Fee Schedule (MPFS) Final Rule, effective January 1, 2022. The rule reduces Non-Facility Practice Expense Relative Value Units, impacting reimbursement for over 600 procedures, including the UroLift System. CEO Liam Kelly expressed disappointment, noting potential patient migration to outpatient settings due to reimbursement changes. The UroLift CPT codes will see fee reductions of 8% and 11%, respectively, and a phased implementation over four years. Financial implications will be discussed in Q4 2021 results.
Teleflex (NYSE: TFX) announced that its UroLift® System won a Bronze Award for 'Best New Branded Television Campaign' and an Honorable Mention for 'Best Branded Website' at the DTC National Advertising Awards. The successful 25-week campaign highlighted lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) and resulted in a 146% increase in website traffic. This recognition showcases Teleflex's creativity in a competitive space dominated by larger pharmaceutical companies.
Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on December 15, 2021, to shareholders recorded by close of business on November 15, 2021. This move reflects the company's commitment to delivering value to its shareholders. Teleflex is a global provider of medical technologies, focusing on improving health and quality of life through innovative solutions in various medical fields. For more details, visit teleflex.com.
Teleflex reported strong financial results for Q3 2021, with revenues of $700.3 million, reflecting an 11.5% year-over-year increase. GAAP diluted EPS rose to $4.20, up from $2.46 a year prior, while adjusted diluted EPS reached $3.51, a 26.7% increase. Despite these positive results, the company lowered its revenue growth guidance due to COVID-19 impacts, now projecting 10-11% GAAP revenue growth and 8-9% constant currency growth. CEO Liam Kelly noted challenges, particularly for the UroLift product line, but emphasized the benefits of a diversified product portfolio.
Teleflex (NYSE: TFX) has completed patient enrollment in a clinical study assessing the QuikClot Control+® Hemostatic Device for mild to moderate bleeding during cardiac surgeries. The study, which aimed to measure hemostasis rates, enrolled 231 patients across seven sites, finishing three months ahead of schedule. Principal investigators express optimism about sharing findings related to various cardiac procedures. The QuikClot Control+® is FDA-cleared for severe bleeding but is investigational in this study, with plans for a 510(k) filing upon analysis completion.
Teleflex Incorporated (NYSE: TFX) will host a conference call to discuss its third quarter financial results on October 28, 2021, at 8:00 a.m. Eastern Time. Interested parties can register for the call via a provided link, which will also allow access to a live audio webcast on the company's website. An audio replay will be available following the call. Teleflex is a global provider of medical technologies, focusing on innovation to meet clinical needs and improve healthcare outcomes.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
